176 related articles for article (PubMed ID: 35444936)
1. Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib.
Li J; Feng Y; Tan Y; Duan Q; Zhang Q
Front Oncol; 2022; 12():863560. PubMed ID: 35444936
[TBL] [Abstract][Full Text] [Related]
2. A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.
Gu L; Zhao Y; Wen F; Zhang D; Cai J; Chen Z
Anticancer Drugs; 2023 Sep; 34(8):949-953. PubMed ID: 36846984
[TBL] [Abstract][Full Text] [Related]
3. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review.
Tian J; Lin Z; Chen Y; Fu Y; Ding Z
Front Oncol; 2022; 12():1006634. PubMed ID: 36387081
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring
Yu Y; Ren Y; Fang J; Cao L; Liang Z; Guo Q; Han S; Ji Z; Wang Y; Sun Y; Chen Y; Li X; Xu H; Zhou J; Jiang L; Cheng Y; Han Z; Shi J; Chen G; Ma R; Fan Y; Sun S; Jiao L; Jia X; Wang L; Lu P; Xu Q; Luo X; Su W; Lu S
Ther Adv Med Oncol; 2022; 14():17588359221133546. PubMed ID: 36339926
[TBL] [Abstract][Full Text] [Related]
5. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
6. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
[TBL] [Abstract][Full Text] [Related]
7. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Li J; Luo X; Wang L; Ren Y; Su W
Lancet Respir Med; 2021 Oct; 9(10):1154-1164. PubMed ID: 34166627
[TBL] [Abstract][Full Text] [Related]
8. Use of savolitinib as neoadjuvant therapy for non-small cell lung cancer patient with MET exon 14 skipping alterations: A case report.
Zhang Y; Zhang H; Wang H; Zeng J; Zhang B; Zhou N; Zu L; Song Z; Wang C; Xu S
Front Oncol; 2022; 12():968030. PubMed ID: 36176406
[TBL] [Abstract][Full Text] [Related]
9. Detection of
Subramanian J; Tawfik O
Expert Rev Anticancer Ther; 2021 Aug; 21(8):877-886. PubMed ID: 33957836
[No Abstract] [Full Text] [Related]
10. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
11. Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration-A Narrative Review.
Zhu X; Lu Y; Lu S
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551608
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel MET Exon 14 Skipping Variants in Non-Small Cell Lung Cancer Patients: A Prototype Workflow Involving in Silico Prediction and RT-PCR.
Das R; Jakubowski MA; Spildener J; Cheng YW
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230737
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring
Fu M; Feng CM; Xia DQ; Ji ZM; Xia HL; Hu NN; Leng ZJ; Xie W; Fang Y; Cao LJ; Zhang JQ
Front Oncol; 2022; 12():954886. PubMed ID: 36052259
[No Abstract] [Full Text] [Related]
14. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal-epithelial transition exon 14 skipping mutation: a case report and literature review.
Chen L; Chen JF; He JT; Rong H; Zhuang X; Peng J
Anticancer Drugs; 2024 Jun; 35(5):445-449. PubMed ID: 38385995
[TBL] [Abstract][Full Text] [Related]
16. Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring
Han S; Fang J; Lu S; Wang L; Li J; Cheng M; Ren Y; Su W
Onco Targets Ther; 2019; 12():7323-7328. PubMed ID: 31564914
[TBL] [Abstract][Full Text] [Related]
17. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.
Liu L; Kalyani FS; Yang H; Zhou C; Xiong Y; Zhu S; Yang N; Qu J
Front Oncol; 2021; 11():649766. PubMed ID: 34249687
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring
Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Fan S; Yu J; Lu P; Luo X; Su W
JTO Clin Res Rep; 2022 Oct; 3(10):100407. PubMed ID: 36217329
[TBL] [Abstract][Full Text] [Related]
19. Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.
Shi M; Ma J; Feng M; Liang L; Chen H; Wang T; Xie Z
Cancer Genet; 2021 Aug; 256-257():62-67. PubMed ID: 33905998
[TBL] [Abstract][Full Text] [Related]
20. Incidence and PD-L1 Expression of
Xu Z; Li H; Dong Y; Cheng P; Luo F; Fu S; Gao M; Kong L; Che N
Onco Targets Ther; 2020; 13():6245-6253. PubMed ID: 32669854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]